Journal
ONCOGENE
Volume 32, Issue 3, Pages 277-285Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2012.55
Keywords
microRNAs; prostate carcinoma; androgen receptor signaling; MAPK pathway; microRNA targets
Funding
- Medical Faculty of the University of Leipzig through funding of the Interdisciplinary Center for Clinical Research
- grant 'Sequence and functional analysis of non-coding RNA in prostate carcinoma' [formel.1]
- European Framework Programme 6 Project SYNLET [043312]
- Initiative and Networking Fund one of the Helmholtz Association [VH-NG-738]
- LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig
- European Social Fund
- Free State of Saxony
Ask authors/readers for more resources
With similar to 30 000 deaths annually in the United States, prostate cancer (PCa) is a major oncologic disease. Here we show that the microRNAs miR-130a, miR-203 and miR-205 jointly interfere with the two major oncogenic pathways in prostate carcinoma and are downregulated in cancer tissue. Using transcriptomics we show that the microRNAs repress several gene products known to be overexpressed in this cancer. Argonaute 2 (AGO2) co-immunoprecipitation, reporter assays and western blot analysis demonstrate that the microRNAs directly target several components of the mitogen-activated protein kinase (MAPK) and androgen receptor (AR) signaling pathways, among those several AR coregulators and HRAS (Harvey rat sarcoma viral oncogene homolog), and repress signaling activity. Both pathways are central for the development of the primary tumor and in particular the progression to its incurable castration-resistant form. Reconstitution of the microRNAs in LNCaP PCa cells induce morphological changes, which resemble the effect of androgen deprivation, and jointly impair tumor cell growth by induction of apoptosis and cell cycle arrest. We therefore propose that these microRNAs jointly act as tumor suppressors in prostate carcinoma and might interfere with progression to castration resistance. Oncogene (2013) 32, 277-285; doi:10.1038/onc.2012.55; published online 5 March 2012
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available